Products:

Innovative therapies
                         Superior outcomes

 

  Latest News:


  March 2014:

      Paradox Pharmaceuticals chosen for TVC semifinals:



   June 2014:

      AD 198 study published in recent journal.

      


Functionally redefining anthracyclines to create more clinically effective and cost-effective non-cardiotoxic and cardioprotective agents for treating cancer in humans and companion animals.